艾普拉唑肠溶片对十二指肠溃疡的疗效及安全性评价Evaluation of Efficacy and Safety of Ilaprazole on Duodenal Ulcer
秦湘红,王韫哲,胡海棠
QIN Xianghong,WANG Yunzhe,HU Haitang
摘要(Abstract)：
目的对艾普拉唑肠溶片治疗十二指肠溃疡的疗效和安全性进行分析。方法选择经胃镜检查证实为活动性十二指肠溃疡并按医嘱服用艾普拉唑肠溶片(1次5 mg,1日1次,疗程4周)的患者。对艾普拉唑肠溶片治疗十二指肠溃疡的4周疗效和安全性进行分析。结果纳入分析的十二指肠溃疡患者共902例。4周溃疡愈合率84.15%、痊愈率49.45%;4周综合症状改善显效率95.77%、有效率97.66%。共发生不良反应21例,不良反应发生率2.33%,不良反应均为轻中度,且没有明显时间集中现象;不同年龄及性别患者间的疗效和不良反应发生率相似。结论艾普拉唑肠溶片能显著改善十二指肠溃疡患者临床症状、促进溃疡愈合,安全性良好。
OBJECTIVE To evaluate the efficacy and safety of ilaprazole in duodenal ulcer patients.METHODS Active duodenal ulcer patiens were identified by endoscopy.Patients were given ilaprazole 5 mg once a day,4 weeks according to doctor' s orders.After 4 weeks,the efficacy and safety were evaluated and analyzed.RESULTS A total of 902 patients were included.After 4 weeks the healing rate was 84.15%,and the cure rate was 49.45%.The markedly-effective rate and effective rate on total symptoms was 95.77% and 97.66%.Twenty-one patients(2.33%) developed mild-to-moderate side effects during the therapy.The efficacy and adverse reactions were similar between different ages and sexes.CONCLUSION Ilaprazole is efficacy and safety in the treatment of duodenal ulcer patients.
关键词(KeyWords)：
艾普拉唑;十二指肠溃疡;疗效;安全性
ilaprazole;duodenal ulcer;therapeutic effects;safety
基金项目(Foundation): 国家科技重大专项(2014ZX09104002-003)
作者(Author):
秦湘红,王韫哲,胡海棠
QIN Xianghong,WANG Yunzhe,HU Haitang
参考文献(References)：
- [1]Kim E J,Lee R K,Lee S M,et al.General pharmacology of IY-81149:a new proton pump inhibitor[J].Arzneimittel Forschung,2001,51(1):51-59.
- [2]Kwon D,Chae J B,Park C W,et al.Effects of IY-81149,a newly developed proton pump inhibitor,on gastric acid secretion in vitro and in vivo[J].Arzneimittel Forschung,2001,51(3):204-213.
- [3]Periclou A P,Goldwater R,Lee S M,et al.A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease[J].Clin Pharmacol Ther,2000,68(3):304-311.
- [4]周丽雅,林三仁,杨云生,等.艾普拉唑对十二指肠溃疡患者胃内p H值的影响[J].中华内科杂志,2010,49(4):290-292.
- [5]林三仁.消化系统疾病电子内镜图谱[M].北京:北京大学医学出版社,2003.
- [6]Ho K Y,Kuan A,Zano F,et al.Randomized,parallel,double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers[J].Gastroenterol,2009,44(7):697-707.
- [7]Ling W,Liya Z,Sanren L,et al.A new PPI,ilaprazole compared with omeprazole in the treatment of duodenal ulcer:a randomized double-blind multicenter trial[J].Clin Gastroenterol,2011,45(4):322-329.
- [8]艾普拉唑临床协作组.艾普拉唑肠溶片治疗十二指肠溃疡的多中心、随机、双盲、阳性平行对照临床研究[J].中华消化杂志,2009,29(8):542-546.
- [9]艾普拉唑临床协作组.艾普拉唑治疗十二指肠溃疡及CYP2C19代谢型对疗效影响的多中心临床研究[J].中华消化内镜杂志,2009,26(9):475-479.
- [10]Ling W,Liya Z,Sanren L,et al.Ilaprazole for the treatment of duodenal ulcer:a randomized,double-blind and controlled phase III trial[J].Curr Med Res Opin,2012,28(1):101-109.
- [11]边壮,田琳,高敏照,等.珠海市部分医院使用艾普拉唑肠溶片的安全性评价[J].中国医院药学杂志,2013,33(17):1440-1442.
- [12]秦湘红.77例艾普拉唑肠溶片不良反应分析[J].今日药学,2017,27(4):265-268.
- [13]龚伟,姜泊.质子泵抑制剂在消化性溃疡领域中的治疗及应用进展[J].中国处方药,2008,76(7):44-45.
- [14]王安起.质子泵抑制剂不良反应文献分析[J].中国药物警戒,2013,10(11):683-686.